Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy

Nephrology Dialysis Transplantation

Volumn 22, Issue 7, 2007, Pages 1943-1949

  Jin, Hui Min ^a   Pan, Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin type 1 receptor blocker (ARB); Glucose homeostasis; Insulin; Losartan; Nephropathy; Type 2 diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD GLUCOSE; C-PEPTIDE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LOSARTAN; MALE; MIDDLE AGED; PROTEINURIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547843572     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm049     Document Type: Article

References (36)

1. Rao RH. Pressor doses of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats. J Endocrinol 1996; 148: 311-318
2. Ogihara T, Asano T, Ando K et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-879
3. Clasen R, Schupp M, Foryst-Ludwig A et al. PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143
4. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial. Lancet 1999; 353: 611-616
5. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003
6. Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885
7. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890
8. Picard F, Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 2002; 22: 167-197
9. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109: 2054-2057
10. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14: S73-s86
11. Lerch M, Teuscher AU, Beissner P, Schneider M, Shaw SG, Weidmann P. Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998; 31: 576-580
12. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093-1097
13. Paolisso G, Tagliamonte MR, Gambardella A et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997; 11: 307-312
14. Lozano V, Llisterri JL, Aznar J et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16: 85-89
15. Lewis EJ, Lawrence GH, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
16. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
17. Appel GB, Radhakrishnan J, Avram MM et al. Analysis of metabolic parameters as predictors of risk the RENAAL study. Diabetes Care 2003; 26: 1402-1407
18. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: An observational study 16,100 patients in primary care. Curr Med Res Opin 2004; 10: 1625-1631
19. Saiki A, Ohira M, Endo K et al. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract 2006; 3: 242-248
20. Hanson RL, Pratley RE, Bogardus C et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000; 151: 190-198
21. Knowler WC, Hamman RF, Edelstein SL et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419
23. Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452
24. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23: 891-898
25. Nielsen S, Hove KY, Dollerup J et al. Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetes Obes Metab 2001; 3: 463-471
26. Murali B, Goyal RK. Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. Pharmacol Res 2001; 44: 385-389
27. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006; 55: 367-374
28. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6-13
29. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1413-1418
30. Ruilope LM, Segura J. Losartan and other angiotensin antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial of evidence. Clin Ther 2003; 25: 3044-3064
31. Bilous RW. Angiotensin II receptor blockade and type 2 diabetic nephropathy. Br J Diabetes Vasc Dis 2002; 2: 101-105
32. Brenner BM, Cooper ME, Zeeuw DD et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
33. Fishman EZ, Tenenbaum A, Motro M. Losartan and diabetic nephropathy: commentaries on the RENAAL study. Cardiovasc Diabetol 2002; 1: 2-4
34. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248
35. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277
36. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity and cardiovascular disease. Biachimie 2004; 86: 779-784